semaglutide and factor v leiden Thrombophilia Factor V Leiden G1691A and

However, further in vitro assays showed a different pharmacological profile, since although the effect on cAMP was notable, we did not observe additional significant effects on -arrestin recruitment activation, therefore providing a similar profile than other non-peptidic agonists like CHU-128 and TT-OAD2

Funding Open Access funding provided by Osaka University

This finding is consistent across multiple GLP-1 studies, suggesting that stopping any appetite-suppressing medication typically results in substantial weight regain unless lifestyle changes are extreme and perfectly maintained

The rate of osteoporosis, a disease where the bones become fragile and brittle, was 3.2% in the group not taking the drug, compared to 4.1% in the GLP-1-taking group